Knowledge Hub

Explore Global Prostate Cancer Therapeutics Market To 2020

Press Release   •   Feb 06, 2017 06:45 EST

Global Prostate Cancer Therapeutics Market Overview

The prostate cancer drugs market is expected to nearly double by 2020, due to the introduction of new, more expensive drugs. Prostate Cancer is the most frequently diagnosed cancer in men. In terms of loss of life from any disease, prostate cancer ranks eleventh; and it ranks sixth in terms of cancer–related mortality in men. The prostate cancer market has a huge demand for new and novel drugs that address unmet needs such as improved survival time, less toxicity, increased progression free survival, increased effectiveness, and lower cost. The global market for the prostate cancer therapeutics market is increasing, driven primarily by the growth in the hormone–refractory prostate cancer therapeutics market. Although, the prostate cancer market faces some hindrances such as the high cost of prostate cancer drugs, the market for prostate cancer drugs is likely to rise in the future.

Global Prostate Cancer Drugs Analysis: Zytiga was the leading prostate cancer drugs in 2014 being followed by Xtandi drugs. In prostate cancer drugs market, Leuplin and Zoladex stand at the third and fourth position respectively in 2014, while Lupron stands at the fifth position in the same year. Bayer's cancer drug Xofigo is also increasing its market share. Decapeptyl, Taxotere, Jevtana and Provenge are the other popular prostate cancer drugs in the global market.

Renub Research report titled “Global Prostate Cancer Therapeutics Market to 2020” provides a comprehensive assessment of the fast–evolving, high–growth of Prostate Cancer Therapeutics Market. This 80 page report with35 Figures and 2 Tables analyses the Prostate Cancer Therapy Drugs Market, driving factors and challenges for prostate cancer market landscape.

Download Sample Copy of Report at

The report covers the following:

1. Global Prostate Cancer – Hormonal Therapy Drugs Market

  • Luteinizing Hormone–Releasing Hormone (LHRH) Antagonists
  • 1. Zytiga

    2. Gonax

  • Luteinizing Hormone–Releasing Hormone (LHRH) Analogs
  • 1. Lupron

    2. Zoladex

    3. Decapeptyl

    4. Eligard

    5. Vantas

    6. Leuplin

  • Anti–Androgens
  • 1. Casodex

    2. Xtandi or MDV3100

    3. Xtandi US or MDV3100

    2. Global Prostate Cancer Chemotherapy Drugs Market

    1. Taxotere

    2. Jevtana

    3. Global Prostate Cancer Immunotherapy Drugs Market

    1. Provenge

    4. Global Prostate Cancer Targeted Therapy Drugs Market

    • 1.Xofigo or Alpharadin